Bartlett & Co. LLC Buys 58,482 Shares of Bristol-Myers Squibb Co (BMY)

Bartlett & Co. LLC raised its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 13.3% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 498,123 shares of the biopharmaceutical company’s stock after purchasing an additional 58,482 shares during the period. Bartlett & Co. LLC’s holdings in Bristol-Myers Squibb were worth $23,765,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Capital Financial Planning LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $28,000. Financial Gravity Wealth Inc. purchased a new stake in shares of Bristol-Myers Squibb in the first quarter worth about $26,000. Well Done LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $30,000. Riverview Trust Co purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $33,000. Finally, Trust Department MB Financial Bank N A purchased a new stake in shares of Bristol-Myers Squibb in the first quarter worth about $32,000. 74.03% of the stock is owned by institutional investors and hedge funds.

BMY has been the topic of a number of research analyst reports. Societe Generale upgraded Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a research report on Tuesday, January 15th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. Bank of America set a $53.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Friday, January 25th. Credit Suisse Group set a $59.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, February 4th. Finally, BMO Capital Markets restated a “buy” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, February 19th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $57.64.

Shares of BMY stock opened at $47.01 on Friday. Bristol-Myers Squibb Co has a 1 year low of $44.30 and a 1 year high of $63.69. The company has a current ratio of 1.93, a quick ratio of 1.79 and a debt-to-equity ratio of 0.37. The company has a market cap of $77.25 billion, a price-to-earnings ratio of 11.81, a P/E/G ratio of 2.21 and a beta of 0.77.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.01. The business had revenue of $5.92 billion for the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a return on equity of 48.72% and a net margin of 22.23%. The company’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.94 earnings per share. On average, equities research analysts anticipate that Bristol-Myers Squibb Co will post 4.18 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were paid a dividend of $0.41 per share. The ex-dividend date was Thursday, April 4th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.49%. Bristol-Myers Squibb’s dividend payout ratio is 41.21%.

TRADEMARK VIOLATION NOTICE: “Bartlett & Co. LLC Buys 58,482 Shares of Bristol-Myers Squibb Co (BMY)” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2019/05/12/bartlett-co-llc-buys-58482-shares-of-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: Key terms to understand channel trading

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply